RenovoRx To Present New Clinical Data Abstract From PK And Pharmacodynamic Sub‑Study Of Ongoing Phase III TIGeR‑PaC Clinical Trial At 2026 ASCO GI

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery Approach

Data Shows a PK Profile that May Improve Clinical Efficacy and Decrease Clinical Side Effects with TAMP and Intra-Arterial Gemcitabine Versus Standard of Care Chemotherapy

MOUNTAIN VIEW, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced that a new clinical data abstract from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 ("ASCO GI"), being held today through January 10th in San Francisco, California.

The abstract, titled "Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial," was led by Dr. Paula M. Novelli of the University of Pittsburgh Medical Center (UPMC). The data presented is from a sub-study of RenovoRx's ongoing Phase III TIGeR-PaC clinical trial (NCT03257033), which is evaluating the use of intra-arterial gemcitabine (IAG), a drug-device combination product candidate that uses the Company's patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, in treating locally advanced pancreatic cancer (LAPC).

The abstract concludes that TAMP and IAG resulted in reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared with IV gemcitabine. Also, with IAG administration, a direct correlation was observed between the increased metabolite levels and reduced CA 19-9, a biomarker commonly used to assess potential chemotherapy response. By decreasing systemic levels of gemcitabine, through limited systemic exposure and rapid conversion to an inactive metabolite, this drug-delivery approach may both increase local drug potency and reduce the negative side effects common to patients with pancreatic cancer.